Valganciclovir as Add-on to Standard Therapy in Glioblastoma Patients.

Giuseppe StragliottoMattia Russel PantaloneAfsar RahbarJiri BartekCecilia Söderberg-Naucler

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Valganciclovir prolonged median OS of patients with newly diagnosed glioblastoma (with methylated or unmethylated MGMT promoter gene) and was safe to use.

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
chronic kidney disease
dna methylation
prognostic factors
genome wide
stem cells
mesenchymal stem cells
cell therapy
genome wide identification